Home » Topics » Regulatory » EMA

EMA
RSS

U.S. priority review and E.U. accelerated assessment granted for Kymriah

Jan. 17, 2018

EMA accepts Evenity MAA in osteoporosis

Jan. 8, 2018

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Jan. 8, 2018

EMA accepts CMA application for avacopan for ANCA-associated vasculitis

Jan. 4, 2018

Cascadian Therapeutics receives pediatric investigation plan waiver from EMA for tucatinib

Jan. 3, 2018

BiondVax Pharmaceuticals planning phase III study of universal flu vaccine

Dec. 29, 2017

EMA committee recommends against approval of Aplidin for multiple myeloma.

Dec. 19, 2017

Bristol-Myers Squibb's Yervoy recommended for approval in Europe for pediatric melanoma

Dec. 19, 2017

EMA committee recommends approval of Alkindi for pediatric adrenal insufficiency

Dec. 18, 2017

EMA committee recommends approval of Ozempic for type 2 diabetes

Dec. 18, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...